At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 543 enrolled
Drug / intervention
insulin degludec/insulin aspart +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes BOOST: INTENSIFY PREMIX/ALL 2
In Brief
A Phase 3 clinical trial evaluating insulin degludec/insulin aspart and biphasic insulin aspart for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 543 participants across 42 sites.
Detailed Summary
This trial is conducted in Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart and BIAsp 30 in subjects with type 2 diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Diabetes Mellitus, Type 2
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedMay 2016
Primary CompletionMay 2017
Study CompletionJun 2017
TodayJul 2026
First PostedMay 5, 2016
Enrollment StartMay 3, 2016
Primary CompletionMay 19, 2017
Study CompletionJun 19, 2017
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 10.2 years ago
Interventions
insulin degludec/insulin aspartdrug
Twice daily subcutaneous (sc, under the skin) injection.
biphasic insulin aspartdrug
Twice daily subcutaneous (sc, under the skin) injection.